Abstract
Objectives: The study aimed to identify the antidiabetic compounds purified from stem bark of Anogeissus leiocarpus and propose the mechanisms of action.
Design: Anogeissus leiocarpus stem bark was purified through ethyl acetate and n-hexane with minor exceptions. For very clear separation, cold acetone was added to trigger the precipitation. The precipitate was dissolved with a mixture of DCM:methanol (9:1), adsorbed it to silica gel (5 g), evaporated to free flowing powder and fractionated it over silica gel (50 g) to realize 40 fractions. The gummy fractions were ignored. The light brown powder which possessed antidiabetic effect was selected for Nuclear Magnetic Resonance for structural elucidation.
Nuclear Magnetic Resonance (NMR) and Determination of Structure of Purified Compound: After column chromatography and TLC processes, along with the cold acetone, to the point of crystallization, the purified compounds, the light brown powder, were presented to NMR (Bruker Avance III, Spectrometer frequency 400 MHz; solvents DMSO-do, CDCl3, Acetone-d6. Institute of Chemistry, Strathclyde University Glasgow UK.) for determination of compound structures and analyses.
Results: The NMR spectra and analyses revealed the existence of Betulinic acid and Trimethoxyellagic acid.
Conclusion: We show that Betulinic acid and Trimethoxyellagic acid are potent antidiabetic compounds in the stem bark extract of A. leiocarpus.
Keywords: Anogeissus leiocarpus, Betulinic Acid, Trimethoxyellagic Acid, Antidiabetic agent
Publisher
Society of Pharmaceutical Tecnocrats
Reference68 articles.
1. 1. Quresh M, Gammoh J, Shakil J, Robbins R, Update on management of Type 2 diabetes for cardiologists. Methodist DeBakey Cardiovascular Journal. 2018; 14(4): 273-280. https://doi.org/10.14797/mdcj-14-4-273 PMid:30788013 PMCid:PMC6369620
2. 2. World Health Organization (WHO), GLOBAL report on diabetes 1. Diabetes mellitus-epidemiology. 2. Diabetes mellitus-prevention and control. 3. Diabetes, Gestational 4. Chronic Disease. 5. Public Health. 1. World Health Organization. France 2016
3. 3. Guariguata L, Whiting DR, hambleton I, Beagley J, Linnenkamp U, Shaw JE. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Research Clinical Practice. 2014; 103(2), 137-149. https://doi.org/10.1016/j.diabres.2013.11.002 PMid:24630390
4. 4. Amjad S, Jafri, Sharma AK, Serajuddin M. A novel strategy of nanotized herbal drugs and their delivery in the treatment of diabetes: Present status and future prospects. Journal of Herbal Medicine, 2019; 17:100279. https://doi.org/10.1016/j.hermed.2019.100279
5. 5. Guo W, et al., Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes/Metabolic Research Review. 2020; 36(7): 33319. https://doi.org/10.1002/dmrr.3319 PMid:32233013 PMCid:PMC7228407